Polynucleotide amplification using CRISPR-Cas systems

US12065695B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12065695-B2
Application numberUS-202016735372-A
CountryUS
Kind codeB2
Filing dateJan 6, 2020
Priority dateNov 11, 2014
Publication dateAug 20, 2024
Grant dateAug 20, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A method for amplifying a target nucleic acid including providing a system having a crRNA or a derivative thereof, and a Cas protein or a variant thereof. The crRNA or the derivative thereof contains a target-specific nucleotide region substantially complementary to a region of the target nucleic acid, and contacting the target nucleic acid with the system to form a complex.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for amplifying a target double-stranded nucleic acid comprising a first strand and a second strand, comprising: (a) providing a system comprising: a clustered regularly interspaced short palindromic repeats (CRISPR) RNA (crRNA) and a CRISPR-associated (Cas) protein, wherein the crRNA contains a target-specific nucleotide region complementary to a region of the first strand; (b) contacting the target double-stranded nucleic acid with the system to form a complex comprising a displaced region of the second strand; (c) hybridizing a primer to the displaced region, wherein the primer is immobilized on a substrate, and wherein the primer comprises a sequence complementary to the displaced region, and (d) extending a nucleic acid complementary to the second strand from the primer using a polymerase. 2. The method of claim 1 , wherein the substrate comprises a flow cell. 3. The method of claim 1 , wherein the substrate comprises a bead. 4. The method of claim 1 , further comprising repeating step (a) to step (d). 5. The method of claim 4 , wherein the target double-stranded nucleic acid is exponentially amplified. 6. The method of claim 1 , wherein the system is selected from the group consisting of a Type I CRISPR-Cas system, a Type II CRISPR-Cas system, and a Type III CRISPR-Cas system. 7. The method of claim 1 , wherein the first strand of the target double-stranded nucleic acid comprises a sequence complementary to a 5′-NGG protospacer-adjacent motif (PAM). 8. The method of claim 1 , wherein the first strand of the target double-stranded nucleic acid comprises a universal sequence, and the primer comprises a sequence of a region of the universal sequence. 9. The method of claim 8 , wherein the universal sequence comprises the sequence of SEQ ID NO:03 or SEQ ID NO:04. 10. The method of claim 1 , wherein the primer comprises the sequence of SEQ ID NO:05 or SEQ ID NO:06. 11. The method of claim 1 , wherein the polymerase is a strand-displacing polymerase selected from the group consisting of Bst, Bsu, and Phi29. 12. The method of claim 1 , further comprising: providing a second system comprising: a second crRNA and a second Cas protein, wherein the second crRNA comprises a target-specific nucleotide region complementary to a region of the second strand; contacting the target double-stranded nucleic acid with the second system; hybridizing a second primer to the first strand contacted with the second system, and extending the hybridized second primer. 13. The method of claim 1 , wherein the system further comprises a trans-activating crRNA (tracrRNA). 14. The method of claim 13 , wherein the crRNA is fused to the tracrRNA. 15. The method of claim 1 , wherein the crRNA comprises the sequence of SEQ ID NO: 07 or 08. 16. The method of claim 1 , wherein the target double-stranded nucleic acid comprises the sequence of SEQ ID NO:09 or 10. 17. The method of claim 1 , wherein the primer comprises the sequence of SEQ ID NO:12 or 14.

Assignees

Inventors

Classifications

  • Single or double stranded nucleic acid binding proteins · CPC title

  • DNA polymerase · CPC title

  • Stable introduction of foreign DNA into chromosome · CPC title

  • Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

  • Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12065695B2 cover?
A method for amplifying a target nucleic acid including providing a system having a crRNA or a derivative thereof, and a Cas protein or a variant thereof. The crRNA or the derivative thereof contains a target-specific nucleotide region substantially complementary to a region of the target nucleic acid, and contacting the target nucleic acid with the system to form a complex.
Who is the assignee on this patent?
Illumina Inc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6853. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).